COVID-19 and diabetes mellitus: from pathophysiology to clinical management

Soo Lim, Jae Hyun Bae, Hyuk Sang Kwon, Michael A. Nauck

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients with diabetes mellitus. Furthermore, COVID-19 might also predispose infected individuals to hyperglycaemia. Interacting with other risk factors, hyperglycaemia might modulate immune and inflammatory responses, thus predisposing patients to severe COVID-19 and possible lethal outcomes. Angiotensin-converting enzyme 2 (ACE2), which is part of the renin–angiotensin–aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target. Preliminary data, however, do not suggest a notable effect of glucose-lowering DPP4 inhibitors on SARS-CoV-2 susceptibility. Owing to their pharmacological characteristics, sodium–glucose cotransporter 2 (SGLT2) inhibitors might cause adverse effects in patients with COVID-19 and so cannot be recommended. Currently, insulin should be the main approach to the control of acute glycaemia. Most available evidence does not distinguish between the major types of diabetes mellitus and is related to type 2 diabetes mellitus owing to its high prevalence. However, some limited evidence is now available on type 1 diabetes mellitus and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.

Original languageEnglish
Pages (from-to)11-30
Number of pages20
JournalNature Reviews Endocrinology
Volume17
Issue number1
DOIs
StatePublished - Jan 2021

Fingerprint Dive into the research topics of 'COVID-19 and diabetes mellitus: from pathophysiology to clinical management'. Together they form a unique fingerprint.

Cite this